First patients to receive new 'Smart Bomb' cancer drug in groundbreaking trial
NCT ID NCT06859762
Summary
This is the first study in people to test a new cancer drug called YL217. The main goals are to check its safety, find the right dose, and see if it can shrink tumors in adults with advanced solid tumors, particularly gastrointestinal cancers. YL217 is a type of targeted therapy designed to deliver a powerful chemotherapy drug directly to cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
Contact
-
Cleveland Clinic Taussig Cancer Institute
RECRUITINGCleveland, Ohio, 44195, United States
Contact
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
-
Duke University Medical Center (DUMC)
RECRUITINGDurham, North Carolina, 27710, United States
Contact
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
Contact
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
-
Mayo Clinic Arizona
RECRUITINGPhoenix, Arizona, 85054, United States
Contact
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Bejing, 100730, China
Contact
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact
-
The University of Kansas Cancer Center (KUCC)
RECRUITINGKansas City, Kansas, 66205, United States
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact
-
UCLA Hematology/Oncology - Santa Monica
RECRUITINGSanta Monica, California, 90404, United States
Contact
-
UT Health San Antonio - Mays Cancer Center
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
University of Cincinnati Medical Center
RECRUITINGCincinnati, Ohio, 45219, United States
Contact
-
University of Maryland Medical Center-Greenebaum Cancer Ctr - Medical Oncology
NOT_YET_RECRUITINGBaltimore, Maryland, 21201, United States
Contact
-
University of Wisconsin Health - UW Carbone Cancer Center
NOT_YET_RECRUITINGMadison, Wisconsin, 53792, United States
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06519, United States
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310022, China
Contact
Conditions
Explore the condition pages connected to this study.